News In Brief

Judge rejects Orthofix settlement with feds. ConvaTec purchases catheter-provider 180 Medical. Cook announces new product division. More news briefs.

A trial date has been set for March 11, 2013, in a federal suit against Orthofix Inc., following a judge's rejection of a settlement that had been inked between the bone-growth-stimulator maker and federal attorneys. Orthofix had agreed to pay a $7.8 million fine to settle a guilty plea on the felony count of obstructing a federal audit, but Massachusetts U.S. District Court Judge William G. Young rebuffed the deal, the Massachusetts U.S. Attorney’s office confirmed. The action also may have implications for a $34.2 million civil settlement tied to the same investigation. Federal attorneys say Orthofix engaged in kickbacks and other fraudulent activities in effort to sell and secure reimbursement for its devices. (See Also see "Judge Weighs $42 Million Orthofix Settlement With Feds" - Medtech Insight, 30 July, 2012..) “The company and the government stand behind their agreements and continue to discuss a resolution of the matter following the court’s rejection of the plea,” Orthofix CEO Robert Vaters said.

MobileHelp, based in Boca Raton, Fla., is expanding its capabilities in the mobile personal emergency response system (M-PERS) business through its acquisition of home health monitor maker Halo Monitoring Inc.,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

Roche Diagnostics Day 2025: ‘We Need To Become A Leader In Decentralized Testing’

 

Roche aims to grow its diagnostics sales by mid to high single digits, said CEO of Roche Diagnostics Matt Sause. The company unveiled the Axelios synthesis and sequencing solution and discussed its “long-term commitment” to China, as well as its business strategy for the next five years.

23andMe Purchase Will Let Regeneron Scale Drug Development

 

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

Deals Shaping The Medtech And Diagnostics Industries, March 2025

 
• By 

An interactive look at medtech and diagnostics deals made during March 2025. Data courtesy of Biomedtracker.

Roar Of Eargo-hearX Merger Echoes Through US OTC Hearing Aid Market

 

The firms recently announced they will operate as combined company LXE Hearing marketing Eargo’s namesake line and hearX’s Lexie brands. Eargo majority owner Patient Square Capital added $100m to its investment.

More from Business

Roche Diagnostics Day 2025: ‘We Need To Become A Leader In Decentralized Testing’

 

Roche aims to grow its diagnostics sales by mid to high single digits, said CEO of Roche Diagnostics Matt Sause. The company unveiled the Axelios synthesis and sequencing solution and discussed its “long-term commitment” to China, as well as its business strategy for the next five years.

BD To Shift China-Facing Production, Ramp Up US Output With $2.5B To Counter Tariff Blow

 
• By 

BD is accelerating transitions of product sourcing for China to avoid tariffs. Historically, products like Vacutainer were exported from Sumter, SC, to China, and Flush was shipped from Columbus, NE.

Salvia Bioelectronics Secures $60M In Series B To Advance Chronic Migraine Implant, Eyes US Trials

 
• By 

Medtech Insight spoke with Hubert Martens, CEO of Netherlands-based neuromodulation company Salvia Bioelectronics, about the company’s innovative implant for treating chronic migraines, ongoing clinical trials and plans for US clinical trials and commercialization.